Latest Articles
- Thyroid eye disease: What’s the latest?
A better understanding of the pathophysiology of this autoimmune disorder has led to innovative insights into its treatment, but long-term management remains a challenge.
- Should we continue guideline-directed medical therapy in patients with heart failure with improved ejection fraction?
Therapy should be continued even if left ventricular ejection fraction improves, as normalization or improvement does not guarantee a permanent recovery.
- Multiple scabietic nodules on the scrotum in a patient living with HIV infection
A 21-year-old man presented with pruritic erythematous papules and nodules on the scrotum and linear keratotic burrows on the right wrist.
- Lipoprotein ‘little a’: More than a little target in the management of cardiovascular risk?
Lipoprotein(a) was once believed to play no contributory role in the development of cardiovascular disease. That storyline has since flipped.
- Rethinking recovery in heart failure: Beyond improvement in left ventricular ejection fraction
The authors discuss 3 unresolved questions about de-escalating and escalating guideline-directed medical therapy in patients with improved ejection fraction.
- Teprotumumab for thyroid eye disease: A reality check
Initial enthusiasm for teprotumumab as therapy for thyroid eye disease has been tempered by longitudinal data suggesting that it often does not alter the natural disease course.
Low-dose colchicine for management of coronary artery diseaseCurrent guidelines endorse adding low-dose colchicine to standard medical therapy for coronary artery disease prevention, but data show clinicians remain hesitant to use it for this indication.
- No surprise, all inflammation is not created equal as it relates to cardiovascular disease
It is accepted that inflammation is an important component of atherosclerotic cardiovascular disease, but have we found the right inflammatory target for pharmacologic therapy?
